nodes	percent_of_prediction	percent_of_DWPC	metapath
Vildagliptin—DPP9—prostate gland—urinary bladder cancer	0.107	0.298	CbGeAlD
Vildagliptin—DPP4—prostate gland—urinary bladder cancer	0.041	0.114	CbGeAlD
Vildagliptin—DPP4—seminal vesicle—urinary bladder cancer	0.0346	0.0963	CbGeAlD
Vildagliptin—DPP9—lymph node—urinary bladder cancer	0.0342	0.0951	CbGeAlD
Vildagliptin—DPP4—epithelium—urinary bladder cancer	0.0301	0.0837	CbGeAlD
Vildagliptin—DPP4—smooth muscle tissue—urinary bladder cancer	0.029	0.0807	CbGeAlD
Vildagliptin—DPP4—renal system—urinary bladder cancer	0.0279	0.0776	CbGeAlD
Vildagliptin—DPP4—female reproductive system—urinary bladder cancer	0.0224	0.0622	CbGeAlD
Vildagliptin—DPP4—vagina—urinary bladder cancer	0.0202	0.0562	CbGeAlD
Vildagliptin—Oedema peripheral—Valrubicin—urinary bladder cancer	0.0139	0.0217	CcSEcCtD
Vildagliptin—DPP4—lymph node—urinary bladder cancer	0.0131	0.0364	CbGeAlD
Vildagliptin—Flatulence—Valrubicin—urinary bladder cancer	0.0121	0.0189	CcSEcCtD
Vildagliptin—Blister—Fluorouracil—urinary bladder cancer	0.0112	0.0174	CcSEcCtD
Vildagliptin—Skin exfoliation—Thiotepa—urinary bladder cancer	0.00928	0.0145	CcSEcCtD
Vildagliptin—Infection—Carboplatin—urinary bladder cancer	0.00921	0.0144	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00912	0.0142	CcSEcCtD
Vildagliptin—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.0078	0.0122	CcSEcCtD
Vildagliptin—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00727	0.0114	CcSEcCtD
Vildagliptin—Asthenia—Valrubicin—urinary bladder cancer	0.00718	0.0112	CcSEcCtD
Vildagliptin—Oedema—Mitomycin—urinary bladder cancer	0.00689	0.0108	CcSEcCtD
Vildagliptin—Diarrhoea—Valrubicin—urinary bladder cancer	0.00685	0.0107	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Gemcitabine—urinary bladder cancer	0.00679	0.0106	CcSEcCtD
Vildagliptin—Skin exfoliation—Etoposide—urinary bladder cancer	0.00666	0.0104	CcSEcCtD
Vildagliptin—Dizziness—Valrubicin—urinary bladder cancer	0.00662	0.0103	CcSEcCtD
Vildagliptin—Headache—Valrubicin—urinary bladder cancer	0.00627	0.00979	CcSEcCtD
Vildagliptin—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00621	0.00969	CcSEcCtD
Vildagliptin—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.0061	0.00953	CcSEcCtD
Vildagliptin—Nausea—Valrubicin—urinary bladder cancer	0.00594	0.00928	CcSEcCtD
Vildagliptin—Fatigue—Mitomycin—urinary bladder cancer	0.00594	0.00928	CcSEcCtD
Vildagliptin—Weight increased—Thiotepa—urinary bladder cancer	0.00555	0.00866	CcSEcCtD
Vildagliptin—Liver function test abnormal—Gemcitabine—urinary bladder cancer	0.00548	0.00855	CcSEcCtD
Vildagliptin—Infestation NOS—Thiotepa—urinary bladder cancer	0.00544	0.00849	CcSEcCtD
Vildagliptin—Infestation—Thiotepa—urinary bladder cancer	0.00544	0.00849	CcSEcCtD
Vildagliptin—Blister—Epirubicin—urinary bladder cancer	0.00543	0.00848	CcSEcCtD
Vildagliptin—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00522	0.00815	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.00514	0.00803	CcSEcCtD
Vildagliptin—Blister—Doxorubicin—urinary bladder cancer	0.00502	0.00784	CcSEcCtD
Vildagliptin—Asthenia—Mitomycin—urinary bladder cancer	0.00495	0.00772	CcSEcCtD
Vildagliptin—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00495	0.00772	CcSEcCtD
Vildagliptin—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.0048	0.00749	CcSEcCtD
Vildagliptin—Diarrhoea—Mitomycin—urinary bladder cancer	0.00472	0.00736	CcSEcCtD
Vildagliptin—Pancreatitis—Cisplatin—urinary bladder cancer	0.00469	0.00732	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00469	0.00732	CcSEcCtD
Vildagliptin—Dizziness—Mitomycin—urinary bladder cancer	0.00456	0.00712	CcSEcCtD
Vildagliptin—Infestation—Fluorouracil—urinary bladder cancer	0.0045	0.00702	CcSEcCtD
Vildagliptin—Infestation NOS—Fluorouracil—urinary bladder cancer	0.0045	0.00702	CcSEcCtD
Vildagliptin—Angiopathy—Thiotepa—urinary bladder cancer	0.00443	0.00691	CcSEcCtD
Vildagliptin—Chills—Thiotepa—urinary bladder cancer	0.00438	0.00684	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.00432	0.00675	CcSEcCtD
Vildagliptin—Headache—Mitomycin—urinary bladder cancer	0.00432	0.00674	CcSEcCtD
Vildagliptin—Malnutrition—Thiotepa—urinary bladder cancer	0.00425	0.00663	CcSEcCtD
Vildagliptin—Nausea—Mitomycin—urinary bladder cancer	0.00409	0.00639	CcSEcCtD
Vildagliptin—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00404	0.00631	CcSEcCtD
Vildagliptin—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00403	0.0063	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.00403	0.00629	CcSEcCtD
Vildagliptin—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00399	0.00623	CcSEcCtD
Vildagliptin—Infestation NOS—Etoposide—urinary bladder cancer	0.0039	0.0061	CcSEcCtD
Vildagliptin—Infestation—Etoposide—urinary bladder cancer	0.0039	0.0061	CcSEcCtD
Vildagliptin—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00376	0.00587	CcSEcCtD
Vildagliptin—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00374	0.00583	CcSEcCtD
Vildagliptin—Angiopathy—Gemcitabine—urinary bladder cancer	0.00372	0.00581	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.00369	0.00577	CcSEcCtD
Vildagliptin—Chills—Gemcitabine—urinary bladder cancer	0.00368	0.00575	CcSEcCtD
Vildagliptin—Arthralgia—Thiotepa—urinary bladder cancer	0.00362	0.00565	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00359	0.00561	CcSEcCtD
Vildagliptin—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.00346	0.0054	CcSEcCtD
Vildagliptin—Infection—Thiotepa—urinary bladder cancer	0.00344	0.00538	CcSEcCtD
Vildagliptin—Nervous system disorder—Thiotepa—urinary bladder cancer	0.0034	0.00531	CcSEcCtD
Vildagliptin—Skin disorder—Thiotepa—urinary bladder cancer	0.00337	0.00526	CcSEcCtD
Vildagliptin—Malnutrition—Cisplatin—urinary bladder cancer	0.00333	0.0052	CcSEcCtD
Vildagliptin—Flatulence—Cisplatin—urinary bladder cancer	0.00328	0.00512	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00325	0.00507	CcSEcCtD
Vildagliptin—Angiopathy—Etoposide—urinary bladder cancer	0.00318	0.00497	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00316	0.00493	CcSEcCtD
Vildagliptin—Chills—Etoposide—urinary bladder cancer	0.00315	0.00491	CcSEcCtD
Vildagliptin—Tremor—Cisplatin—urinary bladder cancer	0.00312	0.00487	CcSEcCtD
Vildagliptin—Arthralgia—Gemcitabine—urinary bladder cancer	0.00304	0.00475	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00302	0.00472	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00301	0.00469	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00299	0.00467	CcSEcCtD
Vildagliptin—Fatigue—Thiotepa—urinary bladder cancer	0.00299	0.00467	CcSEcCtD
Vildagliptin—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00297	0.00464	CcSEcCtD
Vildagliptin—Constipation—Thiotepa—urinary bladder cancer	0.00296	0.00463	CcSEcCtD
Vildagliptin—Oedema—Gemcitabine—urinary bladder cancer	0.00292	0.00455	CcSEcCtD
Vildagliptin—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00291	0.00454	CcSEcCtD
Vildagliptin—Infection—Gemcitabine—urinary bladder cancer	0.0029	0.00452	CcSEcCtD
Vildagliptin—Oedema—Fluorouracil—urinary bladder cancer	0.00287	0.00448	CcSEcCtD
Vildagliptin—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00286	0.00447	CcSEcCtD
Vildagliptin—Infection—Fluorouracil—urinary bladder cancer	0.00285	0.00445	CcSEcCtD
Vildagliptin—Skin disorder—Gemcitabine—urinary bladder cancer	0.00283	0.00442	CcSEcCtD
Vildagliptin—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00282	0.0044	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00282	0.0044	CcSEcCtD
Vildagliptin—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00281	0.00439	CcSEcCtD
Vildagliptin—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.0028	0.00437	CcSEcCtD
Vildagliptin—Urticaria—Thiotepa—urinary bladder cancer	0.00275	0.0043	CcSEcCtD
Vildagliptin—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00275	0.00429	CcSEcCtD
Vildagliptin—Oedema—Cisplatin—urinary bladder cancer	0.00272	0.00424	CcSEcCtD
Vildagliptin—Infection—Cisplatin—urinary bladder cancer	0.0027	0.00422	CcSEcCtD
Vildagliptin—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00269	0.0042	CcSEcCtD
Vildagliptin—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00267	0.00416	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00266	0.00415	CcSEcCtD
Vildagliptin—Skin disorder—Cisplatin—urinary bladder cancer	0.00264	0.00412	CcSEcCtD
Vildagliptin—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00263	0.0041	CcSEcCtD
Vildagliptin—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00262	0.00409	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00261	0.00408	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00258	0.00403	CcSEcCtD
Vildagliptin—Pancreatitis—Methotrexate—urinary bladder cancer	0.00257	0.00402	CcSEcCtD
Vildagliptin—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00254	0.00397	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00252	0.00393	CcSEcCtD
Vildagliptin—Fatigue—Gemcitabine—urinary bladder cancer	0.00251	0.00393	CcSEcCtD
Vildagliptin—Constipation—Gemcitabine—urinary bladder cancer	0.00249	0.00389	CcSEcCtD
Vildagliptin—Asthenia—Thiotepa—urinary bladder cancer	0.00249	0.00388	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00248	0.00387	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00248	0.00387	CcSEcCtD
Vildagliptin—Infection—Etoposide—urinary bladder cancer	0.00247	0.00386	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00244	0.00381	CcSEcCtD
Vildagliptin—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00243	0.00379	CcSEcCtD
Vildagliptin—Skin disorder—Etoposide—urinary bladder cancer	0.00242	0.00378	CcSEcCtD
Vildagliptin—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00241	0.00376	CcSEcCtD
Vildagliptin—Pancreatitis—Epirubicin—urinary bladder cancer	0.00241	0.00376	CcSEcCtD
Vildagliptin—Diarrhoea—Thiotepa—urinary bladder cancer	0.00237	0.0037	CcSEcCtD
Vildagliptin—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00235	0.00367	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00235	0.00366	CcSEcCtD
Vildagliptin—Infestation NOS—Methotrexate—urinary bladder cancer	0.00234	0.00365	CcSEcCtD
Vildagliptin—Infestation—Methotrexate—urinary bladder cancer	0.00234	0.00365	CcSEcCtD
Vildagliptin—Dizziness—Thiotepa—urinary bladder cancer	0.00229	0.00358	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00228	0.00356	CcSEcCtD
Vildagliptin—Urticaria—Fluorouracil—urinary bladder cancer	0.00228	0.00356	CcSEcCtD
Vildagliptin—Weight increased—Epirubicin—urinary bladder cancer	0.00223	0.00349	CcSEcCtD
Vildagliptin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00223	0.00348	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00221	0.00345	CcSEcCtD
Vildagliptin—Infestation—Epirubicin—urinary bladder cancer	0.00219	0.00342	CcSEcCtD
Vildagliptin—Infestation NOS—Epirubicin—urinary bladder cancer	0.00219	0.00342	CcSEcCtD
Vildagliptin—Headache—Thiotepa—urinary bladder cancer	0.00217	0.00339	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00215	0.00336	CcSEcCtD
Vildagliptin—Fatigue—Etoposide—urinary bladder cancer	0.00215	0.00335	CcSEcCtD
Vildagliptin—Constipation—Etoposide—urinary bladder cancer	0.00213	0.00332	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00211	0.0033	CcSEcCtD
Vildagliptin—Hepatitis—Methotrexate—urinary bladder cancer	0.0021	0.00328	CcSEcCtD
Vildagliptin—Asthenia—Gemcitabine—urinary bladder cancer	0.00209	0.00327	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00207	0.00323	CcSEcCtD
Vildagliptin—Weight increased—Doxorubicin—urinary bladder cancer	0.00207	0.00323	CcSEcCtD
Vildagliptin—Nausea—Thiotepa—urinary bladder cancer	0.00206	0.00322	CcSEcCtD
Vildagliptin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00203	0.00316	CcSEcCtD
Vildagliptin—Infestation—Doxorubicin—urinary bladder cancer	0.00203	0.00316	CcSEcCtD
Vildagliptin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.002	0.00312	CcSEcCtD
Vildagliptin—Urticaria—Etoposide—urinary bladder cancer	0.00198	0.00309	CcSEcCtD
Vildagliptin—Hepatitis—Epirubicin—urinary bladder cancer	0.00196	0.00307	CcSEcCtD
Vildagliptin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00196	0.00306	CcSEcCtD
Vildagliptin—Asthenia—Cisplatin—urinary bladder cancer	0.00195	0.00305	CcSEcCtD
Vildagliptin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00194	0.00302	CcSEcCtD
Vildagliptin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00193	0.00301	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00192	0.00299	CcSEcCtD
Vildagliptin—Angiopathy—Methotrexate—urinary bladder cancer	0.0019	0.00297	CcSEcCtD
Vildagliptin—Dizziness—Fluorouracil—urinary bladder cancer	0.0019	0.00296	CcSEcCtD
Vildagliptin—Chills—Methotrexate—urinary bladder cancer	0.00188	0.00294	CcSEcCtD
Vildagliptin—Diarrhoea—Cisplatin—urinary bladder cancer	0.00186	0.0029	CcSEcCtD
Vildagliptin—Malnutrition—Methotrexate—urinary bladder cancer	0.00183	0.00285	CcSEcCtD
Vildagliptin—Headache—Gemcitabine—urinary bladder cancer	0.00183	0.00285	CcSEcCtD
Vildagliptin—Hepatitis—Doxorubicin—urinary bladder cancer	0.00182	0.00284	CcSEcCtD
Vildagliptin—Headache—Fluorouracil—urinary bladder cancer	0.0018	0.0028	CcSEcCtD
Vildagliptin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00179	0.0028	CcSEcCtD
Vildagliptin—Asthenia—Etoposide—urinary bladder cancer	0.00179	0.00279	CcSEcCtD
Vildagliptin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00179	0.00279	CcSEcCtD
Vildagliptin—Angiopathy—Epirubicin—urinary bladder cancer	0.00178	0.00278	CcSEcCtD
Vildagliptin—Chills—Epirubicin—urinary bladder cancer	0.00176	0.00275	CcSEcCtD
Vildagliptin—Nausea—Gemcitabine—urinary bladder cancer	0.00173	0.0027	CcSEcCtD
Vildagliptin—Malnutrition—Epirubicin—urinary bladder cancer	0.00171	0.00267	CcSEcCtD
Vildagliptin—Diarrhoea—Etoposide—urinary bladder cancer	0.0017	0.00266	CcSEcCtD
Vildagliptin—Nausea—Fluorouracil—urinary bladder cancer	0.0017	0.00266	CcSEcCtD
Vildagliptin—Flatulence—Epirubicin—urinary bladder cancer	0.00169	0.00263	CcSEcCtD
Vildagliptin—Angiopathy—Doxorubicin—urinary bladder cancer	0.00165	0.00258	CcSEcCtD
Vildagliptin—Dizziness—Etoposide—urinary bladder cancer	0.00165	0.00257	CcSEcCtD
Vildagliptin—Chills—Doxorubicin—urinary bladder cancer	0.00163	0.00255	CcSEcCtD
Vildagliptin—Nausea—Cisplatin—urinary bladder cancer	0.00161	0.00252	CcSEcCtD
Vildagliptin—Malnutrition—Doxorubicin—urinary bladder cancer	0.00158	0.00247	CcSEcCtD
Vildagliptin—Headache—Etoposide—urinary bladder cancer	0.00156	0.00244	CcSEcCtD
Vildagliptin—Flatulence—Doxorubicin—urinary bladder cancer	0.00156	0.00243	CcSEcCtD
Vildagliptin—Arthralgia—Methotrexate—urinary bladder cancer	0.00156	0.00243	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00155	0.00241	CcSEcCtD
Vildagliptin—Infection—Methotrexate—urinary bladder cancer	0.00148	0.00231	CcSEcCtD
Vildagliptin—Nausea—Etoposide—urinary bladder cancer	0.00148	0.00231	CcSEcCtD
Vildagliptin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00146	0.00228	CcSEcCtD
Vildagliptin—Arthralgia—Epirubicin—urinary bladder cancer	0.00146	0.00227	CcSEcCtD
Vildagliptin—Skin disorder—Methotrexate—urinary bladder cancer	0.00145	0.00226	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00145	0.00226	CcSEcCtD
Vildagliptin—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00144	0.00225	CcSEcCtD
Vildagliptin—Oedema—Epirubicin—urinary bladder cancer	0.0014	0.00218	CcSEcCtD
Vildagliptin—Infection—Epirubicin—urinary bladder cancer	0.00139	0.00217	CcSEcCtD
Vildagliptin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00137	0.00214	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00136	0.00212	CcSEcCtD
Vildagliptin—Skin disorder—Epirubicin—urinary bladder cancer	0.00136	0.00212	CcSEcCtD
Vildagliptin—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00135	0.00211	CcSEcCtD
Vildagliptin—Arthralgia—Doxorubicin—urinary bladder cancer	0.00135	0.0021	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00134	0.00209	CcSEcCtD
Vildagliptin—Oedema—Doxorubicin—urinary bladder cancer	0.00129	0.00202	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00129	0.00201	CcSEcCtD
Vildagliptin—Fatigue—Methotrexate—urinary bladder cancer	0.00129	0.00201	CcSEcCtD
Vildagliptin—Infection—Doxorubicin—urinary bladder cancer	0.00128	0.002	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00127	0.00199	CcSEcCtD
Vildagliptin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00127	0.00198	CcSEcCtD
Vildagliptin—Skin disorder—Doxorubicin—urinary bladder cancer	0.00125	0.00196	CcSEcCtD
Vildagliptin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00125	0.00195	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00121	0.00188	CcSEcCtD
Vildagliptin—Fatigue—Epirubicin—urinary bladder cancer	0.0012	0.00188	CcSEcCtD
Vildagliptin—Constipation—Epirubicin—urinary bladder cancer	0.00119	0.00186	CcSEcCtD
Vildagliptin—Urticaria—Methotrexate—urinary bladder cancer	0.00118	0.00185	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00118	0.00184	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00112	0.00174	CcSEcCtD
Vildagliptin—Fatigue—Doxorubicin—urinary bladder cancer	0.00111	0.00174	CcSEcCtD
Vildagliptin—Urticaria—Epirubicin—urinary bladder cancer	0.00111	0.00173	CcSEcCtD
Vildagliptin—Constipation—Doxorubicin—urinary bladder cancer	0.0011	0.00172	CcSEcCtD
Vildagliptin—Asthenia—Methotrexate—urinary bladder cancer	0.00107	0.00167	CcSEcCtD
Vildagliptin—Urticaria—Doxorubicin—urinary bladder cancer	0.00103	0.0016	CcSEcCtD
Vildagliptin—Diarrhoea—Methotrexate—urinary bladder cancer	0.00102	0.00159	CcSEcCtD
Vildagliptin—Asthenia—Epirubicin—urinary bladder cancer	0.001	0.00156	CcSEcCtD
Vildagliptin—Dizziness—Methotrexate—urinary bladder cancer	0.000986	0.00154	CcSEcCtD
Vildagliptin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000955	0.00149	CcSEcCtD
Vildagliptin—Headache—Methotrexate—urinary bladder cancer	0.000934	0.00146	CcSEcCtD
Vildagliptin—Asthenia—Doxorubicin—urinary bladder cancer	0.000927	0.00145	CcSEcCtD
Vildagliptin—Dizziness—Epirubicin—urinary bladder cancer	0.000923	0.00144	CcSEcCtD
Vildagliptin—Nausea—Methotrexate—urinary bladder cancer	0.000886	0.00138	CcSEcCtD
Vildagliptin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000884	0.00138	CcSEcCtD
Vildagliptin—Headache—Epirubicin—urinary bladder cancer	0.000875	0.00137	CcSEcCtD
Vildagliptin—Dizziness—Doxorubicin—urinary bladder cancer	0.000854	0.00133	CcSEcCtD
Vildagliptin—Nausea—Epirubicin—urinary bladder cancer	0.000829	0.00129	CcSEcCtD
Vildagliptin—Headache—Doxorubicin—urinary bladder cancer	0.000809	0.00126	CcSEcCtD
Vildagliptin—Nausea—Doxorubicin—urinary bladder cancer	0.000767	0.0012	CcSEcCtD
